Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

March 4, 2021

Bharat Biotech’s Phase III interim results of COVAXIN demonstrate efficacy of 81%

Biopharmaceutical company Ocugen has announced that its co-development partner, Bharat Biotech, announced the results of the first interim analysis of its Phase 3 study of COVAXIN, which is a whole virion inactivated Covid vaccine candidate.

Bharat Biotech’s Phase III interim results of COVAXIN demonstrate efficacy of 81%